When Lauren Segal receives a call from her husband one wintry morning in 2014, the furthest thing from her mind is her biopsy results. For two years she’s been living a cancer-free existence after a double mastectomy that has put her in the clear. The call shatters the foundation of her world – the lump she thought was scar tissue is malignant. Her cancer is back.

Cancer: A Love Story is the intimately searing memoir of a four-time cancer survivor. The book magnificently tracks Lauren’s journey to come to terms with the untold challenges of facing the dreaded disease. Forced to face her needle phobia, the author leads the reader into her crumbling world as she confronts the terrors of treatment – from debilitating chemo to nuking radiation. Death is her uninvited companion.

But in the midst of her lonely horror, in a quest for deeper meaning, Lauren discovers the unexpected gift of awareness of unanticipated opportunities that cancer presents – to confront her unmasked humanity – her fears, strengths and weaknesses.

“Throughout my arduous journey into the world of cancer, I have discovered that proximity to death brings with it a new proximity to life. I have learned that luck and unluck, happiness and distress, hope and despair are tightly coiled into a life well lived.” Lauren’s story removes the enormous stigma that still surrounds breast cancer; it tackles the deep fear surrounding diagnoses and treatment and it encourages us to take control of our health. It ultimately triumphs by showing the reader how a person in any unwanted life situation can come out on the other side. The book also provides vital insights for professionals involved in the care of cancer patients and a hugely informative section on chemo tips for those undergoing treatment.

Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.

Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy.

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

This issue of Hematology/Oncology Clinics will focus on lung cancer; specifically, Genomics in lung cancer; Neoadjuvant and adjuvant therapy for NSCLC; Treatment of locally advanced NSCLC; First line systemic therapy for NSCLC; Second line chemotherapy and beyond for NSCLC; Treatment of EGFR mutant tumors; Treatment of ALK positive tumors; New targets in NSCLC; Immunotherapy; Advances in Small cell lung cancer; and many more!

This issue will include articles on Prehabilitation; Building a survivorship program in cancer rehabilitation; Aerobic and resistive training: pragmatic integration in cancer rehabilitation; Alternative exercise traditions in cancer rehabilitation; Cancer treatment induced fibrosis: associated functional morbidity; Cancer-related fatigue: The master disabler; and many more!

This issue of Neuroimaging Clinics of North America focuses on Pediatric Brain Tumors, and is edited by Dr. Lara A. Brandao. Articles will include: Posterior fossa tumors in pediatric patients; Supratentorial tumors in pediatric patients; Brain tumors in the neonate; Pineal region masses in pediatric patients; Sellar and suprasellar tumors in pediatric patients; Extraparenchymal lesions in pediatric patients; Tumor and tumor-like masses in pediatric patients that involve multiple spaces; Neuroimaging of innovative peptide base vaccine therapy in pediatric brain tumors; Advanced MRI in pediatric brain tumors: clinical applications; and much more!

This issue of Hematology/Oncology Clinics of North America is devoted to Neuroendocrine tumors. Articles in this issue include: Pathology Classification of Neuroendocrine Tumors; Clinical Presentation and Diagnosis of Neuroendocrine Tumors; Surgical Management of Gastrointestinal Carcinoid Tumors; Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors; Thymic and Bronchial Carcinoid Tumors; Surgical Management of Pancreatic Neuroendocrine Tumors; Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors; Pheochromocytoma and Paraganglioma; Poorly Differentiated Neuroendocrine Tumors; Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors; Peptide Receptor Radiotherapy in the Treatment of Neuiroendocrine Tumors; Hepatic-Directed Therapies in Patients with Neuroendocrine Tumors; and Neuroendocrine Tumor Clinical Trial Interpretation and Design.

This issue of Clinics in Geriatric Medicine, devoted to Geriatric Oncology, is guest edited by Drs. Harvey J. Cohen and Arati V. Rao of Duke University Medical Center. Articles in this issue include: Cancer and Aging: General Principles, Biology and Geriatric Assessment; Cancer Screening in the Elderly; Cancer Survivorship: Management of Long-term Toxicities; Socioeconomic Considerations and Shared Care Models of Older Cancer Care; Palliative Care and Symptom Management; Management of Prostate Cancer in the Elderly; Management of Breast Cancer in the Elderly; Management of Lung Cancer in the Elderly; Colorectal Cancer in the Elderly; Myelodysplastic Syndrome and Acute Myeloid Leukemia in the Elderly; Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders; and Monoclonal Gammopathies and Multiple Myeloma in the Elderly.

This issue of Thoracic Surgery Clinics of North America focuses on Pulmonary Metastasectomy. Articles will include: Biology of Pulmonary Metastases; Preoperative Evaluations and Indications for Metastasectomy; Open Approaches to Pulmonary Metastases: Thoracotomy and Sternotomy; Ablative Approaches for Pulmonary Metastases: RFA, microwave, SBRT; Role of Lymphadenectomy with Pulmonary Metastasectomy; Results of Pulmonary Resection: Colorectal Carcinoma; Results of Pulmonary Resection: Sarcoma and Germ Cell Tumors; Isolated Lung Perfusion; Immunotherapy; Medical Management of Pulmonary Metastases: Is There a Role for Surgery?; Thoracoscopic Management of Pulmonary Metastases; Results of Pulmonary Resection: Other Epithelial Malignancies; Thoracoscopic Lung Suffusion; and more!

This issue provides much needed updates since Dr. Sheinfeld's issue published in 2007. Dr. Lin has assembled expert authors to provide clinicians with the full breadth of clinical updates on testicular cancer. New to this issue are articles on clinical outcomes, survivorship, and several articles on the management of Nonseminomatous Germ Cell Tumors.

This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.

This issue of Thoracic Surgery Clinics is devoted to "Advanced Lung Cancer: Radical Surgical Therapy" and is edited by Dr. Raja M. Flores. Articles in this outstanding issue include: Surgical Resection of Lung Cancer in the Elderly; Extended Chest Wall Resection and Reconstruction in the Setting of Lung Cancer; The Management of Non-Small Cell Lung Cancer with Oligometastases; Lung Resection in Patients with Marginal Pulmonary Function; Surgery for Small Cell Lung Cancer; Bronchial and Arterial Sleeve Resection after Induction Therapy for Lung Cancer; Advanced Lung Cancer: Aggressive Surgical Therapy Vertebral Body Involvement; Pulmonary Resection after Pneumonectomy; Superior Vena Caval Resection in Lung Cancer; Surgical Resection of Non-Small Cell Lung Cancer with N2 Disease; Lung Transplantation for Multifocal Lung Adenocarcinoma; Extended Resections of Non-Small Cell Lung Cancers Invading the Aorta, Pulmonary Artery, Left Atrium or Esophagus: Can They Be Justified?; VATS Lobectomy after Induction Therapy; Extrapleural Pneumonectomy for Pleural Disease; Carinal Resection, and more!

This issue of Surgical Oncology Clinics of North America, devoted to Imaging in Oncology, is edited by Dr. Vijay Khatri. Articles in this issue include: Imaging of Central Nervous Tumors; Role of Imaging in Head and Neck Malignancies; Imaging of Thoracic Cavity Tumor; Diagnostic Imaging of Hepatobiliary Malignancies; Recent Advances in Genito-Urinary Tract Tumors; Current Status of Imaging for Adrenal Glands; Radiology of Soft Tissue Tumors; Image-Guided Interventions in Oncology; Imaging of Pancreatic Neoplasms; Imaging of Primary Malignant Tumors of Peritoneal and Retroperitoneal Origin; Breast Tumor Imaging; and Application of Intraoperative Imaging in Oncology.

Knowledge of cutaneous lymphomas has been growing significantly as a result of important discoveries in immunology, molecular biology, and immunohistochemistry. Improved clinical pathologic correlation and follow-up data, as well as the synergistic collaboration among different lymphoma registries and specialists from several academic medical centers have greatly contributed to the understanding of the difficult field of cutaneous lymphoproliferative disorders. While these advances have increased understanding of skin lymphomas, they have also produced an extensive and sometimes confusing litany of articles, studies, and classification schemes. This issue on Cutaneous Lymphomas in Surgical Pathology Clinics provides an organized and updated review of this challenging topic by leading experts. It bridges critical knowledge gaps in the diagnosis of cutaneous lymphomas. Sezary Syndrome, Mycosis Fungoides and variants are presented along with B-cell, CD30, lymphoproliferative disorders among others. In addition to multiple clinical and microscopic images, tables and algorithms are presented to aid in diagnosis and staging. Beyond its usefulness to general pathologists, dermatopathologists, and hematopathologists, this information is intended to be helpful for dermatologists, hematologists/oncologists, fellows, and residents.

"Electroporation-Based Therapies for Cancer" reviews electroporation-based clinical studies in hospitals for various cancer treatments, including melanomas, head and neck cancers, chest wall breast carcinomas, and colorectal cancers, as well as research studies in the lab using cell lines, primary cells, and animals.

Cancer kills about one American per minute, amounting to over 500,000 deaths in the United States and millions, worldwide, each year. There is a critical need for safe, effective, and affordable alternative treatment modalities, especially for inoperable, recurring, and chemo-resistant cancers, that do not respond well to current treatment regimen. An electrical-pulse-mediated, enhanced drug delivery technique known as electroporation is one way to effectively treat these patients.

This technique is especially suitable for low- and middle-income countries, where lack of infrastructure and resources leads to cancer diagnoses at late stages. This quick, safe, effective, economical, out-patient-based technique is a boon to these patients for palliative and other care with enhanced quality of life. This book features discussions by interdisciplinary authors-including practicing oncological surgeons, medical professionals, and academic and other researchers-of the basics and clinical medical applications of electroporation.
Provides novel and recent clinical applications of electrochemotherapy for various cancers, including melanomas, sarcomas, superficial extreme melanoma, chest wall breast carcinoma, and colorectal cancersExtensive study of a number of cell lines, including human breast cancer, lung cancer, cervical cancer, leukemia, and mouse breast cancer using both reversible and irreversible electroporation techniquesIn vitro study of delivery of various commonly prescribed/administered breast cancer chemo and hormone drugs, such as Doxorubicin, Paclitaxel, Bleomycin, and Tamoxifen

Cancer can affect people of all ages, and approximately one in three people are estimated to be diagnosed with cancer during their lifetime. Extensive research is being undertaken by many different institutions to explore potential new therapeutics, and biomaterials technology is now being developed to target, treat and prevent cancer. This unique book discusses the role and potential of biomaterials in treating this prevalent disease.
The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics. Chapters in part two discuss synthetic vaccines, proteins and polymers for cancer therapeutics. Part three focusses on theranosis and drug delivery systems, whilst the final set of chapters look at biomaterial therapies and cancer cell interaction.
This extensive book provides a complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancer. Biomaterials for cancer therapeutics is an essential text for academics, scientists and researchers within the biomedical industry, and will also be of interest to clinicians with a research interest in cancer therapies and biomaterials.
A complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancerDiscusses the fundamentals of biomaterials for cancer therapeuticsDiscusses synthetic vaccines, proteins and polymers for cancer therapeutics

The application of nuclear magnetic resonance (NMR) metabolomics in cancer research requires an understanding of the many possibilities that NMR metabolomics can offer, as well as of the specific characteristics of the cancer metabolic phenotype and the open questions in cancer research. NMR metabolomics in cancer research presents a detailed account of the NMR spectroscopy methods applied to metabolomics mixture analysis along with a discussion of their advantages and disadvantages. Following an overview of the potential use of NMR metabolomics in cancer research, the book begins with an examination of the cancer metabolic phenotype and experimental methodology, before moving on to cover data pre-processing and data analysis. Chapters in the latter part of the book look at dynamic metabolic profiling, biomarker discovery, and the application of NMR metabolomics for different types of cancer, before a concluding chapter discusses future perspectives in the field.
Focused description of NMR spectroscopy needed by cancer biologists who are starting to use metabolomicsCurrent overview of knowledge related to the cancer metabolic phenotype from the perspective of metabolomics applicationsInformation about the best practices in NMR metabolomics experimentation and data preprocessing as applied to different sample types

Remarkable advances have occurred since the Series 3 Fascicle published in 1995 with paradigm shifts in every dimension of our understanding of lung tumors including clinical, radiologic, histopathologic, cytopathologic, immunohistochemical, molecular and therapeutic aspects. The molecular revolution leading to effective targeted therapies and breakthroughs in immunotherapy for lung cancer have led to novel approaches incorporating the concept of personalized medicine for patients who historically had little hope. These advances have strengthened the place of pathologists to play a central role in the multidisciplinary team that is now needed to properly diagnose and manage lung cancer patients.

The biological function of clusterin (CLU, also known as ApoJ, SGP2, TRPM2, CLI) has been puzzling researchers since its discovery and characterization in the early 1980s. Approaches such as cloning, expression and functional characterization of the different protein products generated by the CLU gene have now produced a critical mass of information of tremendous biological importance that are teaching us an important lesson in molecular biology of gene expression regulation. This volume brings together the contributions of top researchers in the field, providing an overview and synthesis of the latest thought and findings relating to CLU.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including platelet-derived growth factor in disease, genetic predisposition in tumor development, primary effusion lymphoma, and many more.
Cancer is not one disease, but a group of diseases in which malignant cells grow out of control and spread to other parts of the body. Eventually these cells form a visible mass or tumor. Appropriate treatment for cancer depends on what kind of cancer a person has. The type of cancer is determined by the organ the cancer starts in, the kind of cell from which it is derived, and the appearance of the cancer cells.

After her diagnosis of triple negative breast cancer (TNBC), health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, and how it's treated. While she learned that important research was emerging, she found a noticeable lack of resources on the disease, which affects 70,000 women a year and differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. Hormone negative breast cancer disproportionately affects younger women and African-American women - and it can be more dangerous than other types of breast cancer. But there are many reasons to be hopeful, as Prijatel learned. Through her blog, Positives About Negative, she has met hundreds of women who have told her their stories and shared their fears, confusion, and frustration. After her recovery, she began writing this book to provide the first dedicated resource for women diagnosed with TNBC. Surviving Triple Negative Breast Cancer delivers research-based information on the biology of TNBC; the role of genetics, family history, and race; how to navigate treatment options; and a plethora of strategies to reduce the risk of recurrence, including diet and lifestyle changes. In clear, approachable language, Prijatel provides an accessible guide to understanding a pathology report and a vast array of scientific studies. Woven throughout the book are stories of women who have faced TNBC. These are mothers, wives, daughters, and sisters who went through a variety of medical treatments and then got on with life - one competes in triathlons, two had babies after being treated with chemo, one got remarried in her 50s, and one just celebrated the 30th birthday of the son she was nursing when she was diagnosed. With honesty and humor, Prijatel's inspiring story shows the heart of a survivor. Her message is that TNBC is a disease to take seriously, with proper and occasionally aggressive treatment, but it is not automatically a killer. Most women diagnosed with the disease do survive. Surviving Triple Negative Breast Cancer is a roadmap for women who want to be empowered through their treatment and recovery.

This is the most comprehensive review of the idiotypic network available. All the current knowledge of idiotypes of the various antibodies is incorporated in this volume. The pathogenic role of idiotypes in autoimmunity and cancer is reviewed in depth. The therapeutic part focusses on harnessing anti-idiotypes for treating autoimmunological disorders, and on the employment of idiotypes for vaccines in cancer and infectious diseases, as well as explaining the manipulation of the idiotypic network in autoimmunity and cancer idiotypes and vaccines.

Ook in Engels beskikbaar: Knowledge Beats Cancer
JY HET KANKER! 'n Ystervuis beklem jou hart wanneer jy die diagnose hoor. Ná die skok en ontkenning kom die vrae: Wat gaan nou met my gebeur? Wat is my oorlewingskans?
In Kennis Klop Kanker word die pasiënt, en enigeen wat meer van kanker wil weet, ingelig oor alle fasette van kanker:
Wat kanker presies is en hoe kanker ontstaan
Die omvangsyfer en suksesse van kankerterapieë
Belangrikheid van dieet, noodsaaklike gereelde ondersoeke en selfondersoeke
Die vele vertakkinge en benaderinge van moderne terapieë
Moderne behandelingsmetodes en prognose van algemene kankers (29 tipes)
Deurbrake in molekulêre biologie met minder newe-effekte
Beenmurgstamseloorplanting
Mediane oorlewingstatistiek
Alternatiewe, komplementerende en integrerende terapieë
Pasiëntondersteuning, herstel ná mastektomie, kanker by jongmense en kinders, goeie pynkontrole, versorging van pasiënte met gevorderde kanker
Ondersteuning deur gemeenskapsorganisasies
Skrywer se persoonlike perspektief oor lyding en geloofsgenesing
DIE OUTEUR: Albert Stegmann Alberts is 'n onkoloog wat 33 jaar lank met kankerpasiënte gewerk het. Hy het gespesialiseer in al die vertakkings van kankerterapie. Hy is die outeur van verskeie internasionale publikasies.

How does a pathologist become interested and develop expertise in testicular and paratesticular neoplasms, which are relatively uncommon? The truth is simple-the opportunity to see many cases. The authors of this 5th Series Fascicle have such expertise and share a remarkable range of cases from their institutions as well as from many pathologists throughout the world who have sent them cases in consultation over the years. This fascicle is rich source of material that will be a great resource for practicing pathologists and pathologists in training.